| You are in:Home/Publications/Melanocortin Receptor Agonist (Corticotrophin) in Treatment of Refractory Diabetic nephropathy | |
Dr. Shimaa Salah Ali El-sayed :: Publications: |
|
| Title: | Melanocortin Receptor Agonist (Corticotrophin) in Treatment of
Refractory Diabetic nephropathy |
| Authors: | 1 S.S.El-sayed, 1A.E.Mansour, 1A.T.Mahmoud, 1H.G.Abdelsalam, 1 S.B.Hannalla, 1E.L.El-Shahawy |
| Year: | 2022 |
| Keywords: | Not Available |
| Journal: | Not Available |
| Volume: | Not Available |
| Issue: | Not Available |
| Pages: | Not Available |
| Publisher: | Not Available |
| Local/International: | Local |
| Paper Link: | Not Available |
| Full paper | Shimaa Salah Ali El-sayed_PAPER... (1).pdf |
| Supplementary materials | Not Available |
| Abstract: |
The points of this examination are To evaluate the reaction and adequacy of melanocortin receptor agonist (ACTH) as a treatment for patients with stubborn diabetic nephropathy . This examination was performed on 50 diabetic patients who went to inner medication division at banha college emergency clinic. Patients with diabetic nephropathy gave proteinuria more than 1gm/24hour pee assortment and who are not reacting to against proteinuric measures for at any rate one month of treatment rewarded with engineered ACTH permitting a 6 months development. Result. The essential endpoint was the level of patients accomplishing a total reduction ( |
